참고문헌
- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424. https://doi.org/10.3322/caac.21492
- Dyck PJ, Lais AC, Ohta M, et al. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 1975;50:621-637.
- Broers MC, Bunschoten C, Nieboer D, et al. Incidence and prevalence of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. Neuroepidemiology 2019;52:161-172. https://doi.org/10.1159/000494291
- Malik A, Berry R, Fung BM, et al. Association between chronic inflammatory demyelinating polyneuropathy and gastrointestinal malignancies. Clin J Gastroenterol 2021;14:1-13. https://doi.org/10.1007/s12328-020-01281-7
- Rajabally YA, Attarian S. Chronic inflammatory demyelinating polyneuropathy and malignancy: a systematic review. Muscle Nerve 2018;57:875-883. https://doi.org/10.1002/mus.26028
- Antoine JC, Mosnier JF, Lapras J, et al. Chronic inflammatory demyelinating polyneuropathy associated with carcinoma. J Neurol Neurosurg Psychiatry 1996;60:188-190. https://doi.org/10.1136/jnnp.60.2.188
- Ayyappan S, Day T, Kiers L. Distal acquired demyelinating symmetric (DADS) neuropathy associated with colorectal adenocarcinoma. Muscle Nerve 2015;51:928-931. https://doi.org/10.1002/mus.24510
- Galassi G, Luppi G. Distal acquired demyelinating symmetric neuropathy associated with colorectal adenocarcinoma: should it be termed paraneoplastic? Muscle Nerve 2016;53:658-659. https://doi.org/10.1002/mus.24951
- Bell CE, Seetharam S. Identification of the Schwann cell as a peripheral nervous system cell possessing a differentiation antigen expressed by a human lung tumor. J Immunol 1977;118:826-831. https://doi.org/10.4049/jimmunol.118.3.826
- Kudo M, Noguchi T. Immunoreactive myelin basic protein in tumor cells associated with carcinomatous neuropathy. Am J Clin Pathol 1985;84:741-743. https://doi.org/10.1093/ajcp/84.6.741
- Altermatt HJ, Rodriguez M, Scheithauer BW, et al. Paraneoplastic anti-Purkinje and type I anti-neuronal nuclear autoantibodies bind selectively to central, peripheral, and autonomic nervous system cells. Lab Invest 1991;65:412-420.
- Fuller GN, Spies JM, Pollard JD, et al. Demyelinating neuropathies triggered by melanoma immunotherapy. Neurology 1994;44:2404-2405. https://doi.org/10.1212/WNL.44.12.2404
- Henry K. Paraneoplastic syndromes: definitions, classification, pathophysiology and principles of treatment. Semin Diagn Pathol 2019;36:204-210. https://doi.org/10.1053/j.semdp.2019.01.002
- Jameson JL, Longo DL. Paraneoplastic syndromes: endocrinologic/hematologic. In: Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, editors. Harrison's Principles of Internal Medicine 20th ed. McGraw-Hill Education; 2018.
- Bunschoten C, Jacobs BC, Van den Bergh PYK, et al. Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Lancet Neurol 2019;18:784-794. https://doi.org/10.1016/S1474-4422(19)30144-9
- Van den Bergh PYK, Hadden RDM, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. Eur J Neurol 2010;17:356-363. https://doi.org/10.1111/j.1468-1331.2009.02930.x
- Breiner A, Brannagan TH. Comparison of sensitivity and specificity among 15 criteria for chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2014;50:40-46. https://doi.org/10.1002/mus.24088
- Kuwabara S, Misawa S. Chronic inflammatory demyelinating polyneuropathy. Adv Exp Med Biol 2019;1190:333-343. https://doi.org/10.1007/978-981-32-9636-7_21
- Benson AB, Venook AP, Al-Hawary MM, et al. NCCN guidelines insights: colon cancer, version 2.2018. J Natl Compr Canc Netw 2018;16:359-369. https://doi.org/10.6004/jnccn.2018.0021
- Kakushadze Z, Raghubanshi R, Yu W. Estimating cost savings from early cancer diagnosis. Data 2017;2:30.